Trump announces trade deal with EU following months of negotiations
Compugen Ltd (NASDAQ: NASDAQ:CGEN), a therapeutic discovery company, has seen its stock price touch a 52-week low, reaching a price level of $1.35 USD. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 5.26, indicating robust liquidity. The stock’s technical indicators suggest it may be oversold, one of several insights available through InvestingPro’s comprehensive analysis. This latest dip reflects a significant downturn for the company, which has experienced a 1-year change with a decrease of 43.39%. Despite the challenges, InvestingPro analysis indicates the stock is currently trading below its Fair Value, with analysts setting a target price of $4.00. Investors are closely monitoring the stock as it navigates through a challenging period in the market, with the hope for potential recovery or further developments that may influence the company’s stock performance. For deeper insights, check out the comprehensive Pro Research Report available on InvestingPro, offering detailed analysis of CGEN among 1,400+ US stocks.
In other recent news, Compugen Ltd. reported its fourth-quarter 2024 earnings, revealing a significant miss in both earnings per share (EPS) and revenue compared to market forecasts. The company posted an EPS of -$0.07, falling short of the expected $0.02, and reported revenue of $1.47 million, well below the $11.66 million forecast. Despite these challenges, Compugen (TASE:CGEN) maintains a cash balance of $103.3 million, which is projected to fund operations into 2027. The company continues to advance its clinical programs, notably a pivotal trial for COM701 as a monotherapy for platinum-sensitive ovarian cancer, expected to begin in the second quarter of 2025.
Compugen is also monitoring two licensed programs: rilvegostomig, licensed to AstraZeneca (NASDAQ:AZN), and GS-0321, licensed to Gilead Sciences (NASDAQ:GILD). AstraZeneca’s rilvegostomig is currently in Phase 3 studies, with interim data expected in 2025, while the GS-0321 trial has already commenced. Analyst Tony Blair from Rodman & Renshaw reaffirmed a Buy rating for Compugen, maintaining a $4.00 price target. Blair noted the company’s strategic focus on advancing its clinical pipeline and the potential benefits from partnerships with larger pharmaceutical firms. These developments reflect Compugen’s ongoing efforts to strengthen its position in the oncology sector through innovation and strategic collaborations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.